Department of Biomedical Engineering, Vanderbilt University, 2301 Vanderbilt Place, PMB351826, Nashville, TN, 37235, USA.
Department of Bioengineering, University of Pennsylvania, 2301 240 Skirkanich Hall, 210S. 33rd Street, Philadelphia, PA, 19104-6321, USA.
Nat Commun. 2019 Nov 1;10(1):5012. doi: 10.1038/s41467-019-12906-y.
Peptides and biologics provide unique opportunities to modulate intracellular targets not druggable by conventional small molecules. Most peptides and biologics are fused with cationic uptake moieties or formulated into nanoparticles to facilitate delivery, but these systems typically lack potency due to low uptake and/or entrapment and degradation in endolysosomal compartments. Because most delivery reagents comprise cationic lipids or polymers, there is a lack of reagents specifically optimized to deliver cationic cargo. Herein, we demonstrate the utility of the cytocompatible polymer poly(propylacrylic acid) (PPAA) to potentiate intracellular delivery of cationic biomacromolecules and nano-formulations. This approach demonstrates superior efficacy over all marketed peptide delivery reagents and enhances delivery of nucleic acids and gene editing ribonucleoproteins (RNPs) formulated with both commercially-available and our own custom-synthesized cationic polymer delivery reagents. These results demonstrate the broad potential of PPAA to serve as a platform reagent for the intracellular delivery of cationic cargo.
肽和生物制剂为调节细胞内靶点提供了独特的机会,而这些靶点是传统小分子药物无法作用的。大多数肽和生物制剂与阳离子摄取部分融合或被制成纳米颗粒以促进递药,但这些系统通常由于摄取率低以及/或在内体溶酶体隔室中被截留和降解而缺乏效力。由于大多数递药试剂由阳离子脂质体或聚合物组成,因此缺乏专门用于递送电荷的试剂。在此,我们证明了细胞相容性聚合物聚(丙基丙烯酸)(PPAA)在增强阳离子生物大分子和纳米制剂的细胞内递药方面的效用。与所有市售的肽递药试剂相比,该方法显示出更好的效果,并增强了用市售和我们自己合成的阳离子聚合物递药试剂配制的核酸和基因编辑核糖核蛋白(RNP)的递药效果。这些结果表明,PPAA 具有作为阳离子载体细胞内递药的平台试剂的广泛潜力。